Company intelligence / Profile preview
Boehringer Ingelheim
Ingelheim am Rhein, Rhineland-Palatinate, Germanyboehringer-ingelheim.com ↗
- Ownership
- Private
- Employees
- ~54500
- Development stage
- Other
01
Overview
Boehringer Ingelheim has an ambitious pipeline with the goal of launching 25 new treatments by 2030. The company plans to start 10 new Phase II and Phase III trials over the next 12-18 months. Recent promising candidates include Brigimadlin (MDM2-p53 agonist) for dedifferentiated liposarcoma, zongertinib (HER2 tyrosine kinase inhibitor), and survodutide (glucagon/GLP-1 candidate) for liver disease and obesity[6].
- Therapeutic areas
- GastroenterologyPulmonologyCardiovascularMetabolic DisordersNephrologyOphthalmologyImmunologyDermatologyOncologyNeurologyInfectious Diseases
- Modalities
- Small moleculesbiologicsvaccines
- Industry
- Pharma
02
Drug pipeline
384 assets383 more assets in the full pipeline.
03
Partnerships
Academic researcherspharmaceutical companies
Beyond the preview
Go deeper on Boehringer Ingelheim.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Boehringer Ingelheim.